Vanguard Group Inc. Acquires 3,086,311 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Vanguard Group Inc. increased its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 41.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,587,804 shares of the company's stock after buying an additional 3,086,311 shares during the quarter. Vanguard Group Inc. owned about 6.29% of Allogene Therapeutics worth $33,563,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Great West Life Assurance Co. Can boosted its holdings in shares of Allogene Therapeutics by 26.1% in the 1st quarter. Great West Life Assurance Co. Can now owns 8,827 shares of the company's stock valued at $43,000 after purchasing an additional 1,826 shares in the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Allogene Therapeutics by 11.3% in the 3rd quarter. Ensign Peak Advisors Inc now owns 20,910 shares of the company's stock valued at $226,000 after purchasing an additional 2,120 shares in the last quarter. WINTON GROUP Ltd boosted its holdings in shares of Allogene Therapeutics by 6.4% in the 1st quarter. WINTON GROUP Ltd now owns 37,255 shares of the company's stock valued at $184,000 after purchasing an additional 2,251 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Allogene Therapeutics by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 203,865 shares of the company's stock valued at $1,013,000 after purchasing an additional 2,459 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of Allogene Therapeutics by 24.9% in the 1st quarter. Oppenheimer & Co. Inc. now owns 15,050 shares of the company's stock valued at $137,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 15th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Tuesday, March 19th. Guggenheim cut Allogene Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, January 5th. JMP Securities reiterated a "market perform" rating on shares of Allogene Therapeutics in a research note on Friday, January 5th. Finally, JPMorgan Chase & Co. dropped their price target on Allogene Therapeutics from $9.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, February 27th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.17.

Allogene Therapeutics Stock Down 4.8 %

ALLO traded down $0.19 during midday trading on Friday, hitting $3.80. 2,882,299 shares of the company were exchanged, compared to its average volume of 2,635,534. The firm has a market capitalization of $642.54 million, a P/E ratio of -1.82 and a beta of 0.81. The firm's 50 day moving average price is $4.57 and its 200-day moving average price is $3.53. Allogene Therapeutics, Inc. has a 1-year low of $2.23 and a 1-year high of $6.89.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. On average, sell-side analysts predict that Allogene Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).